








Increased risk of cardiovascular disease and 
increased subclinical atherosclerosis have 
been reported in CYP with PAI when 
compared to healthy children. 
Carotid intima media thickness (CIMT) can 
be used as an early marker of 
cardiovascular disease. 
The severity of adverse metabolic profile 
has been related to the total hydrocortisone 
dose and duration of treatment.
To assess the prevalence of increased 
CIMT, an early marker of cardiovascular 
risk, in children with PAI. 
Children with primary AI treated with 
hydrocortisone (HC) attended the CRF. 
Demographics were recorded, as was 
height, weight and blood pressure. 
Measurements for CIMT were taken 
approximately 0.5cm distal from the 
carotid bulb on the right carotid artery. 
Average measurements were taken of 
these images.
Two sitting blood pressure 
measurements were taken from the left 
arm and an average was ascertained.
Children > 10 years also had 24-hour 
ambulatory blood pressure recorded 
when tolerated. 
These preliminary data show CIMT measurements that are in the normal range, in 
this cohort of CYP with PAI.
Hypertension is evident within this population.
Contrary to historical data, early subclinical atherosclerotic changes have not been 
identified. 
This may reflect good clinical practice. Hydrocortisone doses are reviewed and 
adjust regularly, guided by both clinical and biochemical parameters.  
(Dalla Pozza, Ehringer-
Schetitska et al. 2015)
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17 Children (aged 9.9 ± 4.1 years) participated in 
the cardiovascular aspect of the study. 
3 children had Addison’s, 14 had congenital 
adrenal hyperplasia (9 of whom had salt 
wasting).
2 children could not tolerate ultrasonography.
Table 1. Patient characteristics of children with 
PAI who had CIMT performed.
7 children showed evidence of hypertension on 
sitting blood pressure (>95th centile)
4 children showed evidence of diastolic BP 
>95th centile.
Children with BP readings >95th centile were on 
HC doses 5.6-10.8mg/m2/day and 
fludrocortisone doses 0-175 mcg/day.
Doses were reviewed and adjusted in those with 
hypertension. These measurements will be 
repeated at their next clinic appointment. 
One child has hypertension of unknown cause 
who is currently being investigated.
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Parameter (n = 17) Mean ± SD
Height SDS 0·81 ± 1·34
BMI SDS 0·13 ± 1·21
Height SDS 0·81 ± 1·34
BMI SDS 0·13 ± 1·21
















Table 2. Average sitting blood pressure in 
children with PAI treated with hydrocortisone
Photograph highlighting correct assessment of CIMT1
Median, IQR
CIMT measurement (mm) 0·41 (0·40-0·48)
CIMT measurements were within normal limits when compared 
to that of healthy children.1
Linear regression analysis, adjusted for age, length of time 
since diagnosis/start of hydrocortisone treatment and dose of 
hydrocortisone taken did not show an association with CIMT 
values. 
Table 3. Carotid intima media measurements in children with primary 
adrenal insufficiency
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